{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:30:14Z","timestamp":1794137414234,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40120-024-00653-2","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:02:17Z","timestamp":1725274937000},"page":"1483-1504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-3450","authenticated-orcid":false,"given":"Tim","family":"Hagenacker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Coratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5698-8802","authenticated-orcid":false,"given":"Angela D.","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"653_CR1","doi-asserted-by":"crossref","unstructured":"Darras BT, Markowitz JA, Monani UR, De Vivo DC. Spinal muscular atrophies. In: Darras BT JH, Ryan MM, De Vivo DC, ed. Neuromuscular disorders of infancy, childhood, and adolescence. 2nd ed. Cambridge: Academic Press; 2015.","DOI":"10.1016\/B978-0-12-417044-5.00008-1"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120\u201333.","journal-title":"Lancet"},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2021;35:1317\u201328.","journal-title":"CNS Drugs"},{"key":"653_CR4","doi-asserted-by":"crossref","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323.","DOI":"10.1001\/archneur.1995.00540290108025"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Leary R, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264:1465\u201373.","journal-title":"J Neurol"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/mus.25148","volume":"54","author":"ET Kruitwagen-Van Reenen","year":"2016","unstructured":"Kruitwagen-Van Reenen ET, Wadman RI, Visser-Meily JM, van den Berg LH, Schr\u00f6der C, van der Pol WL. Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle Nerve. 2016;54:850\u20135.","journal-title":"Muscle Nerve"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","volume":"91","author":"P Mongiovi","year":"2018","unstructured":"Mongiovi P, Dilek N, Garland C, et al. Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). Neurology. 2018;91:e1206\u201314.","journal-title":"Neurology"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27:883\u20139.","journal-title":"Neuromuscul Disord"},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, M\u00fcller-Felber W, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve. 2021;63:668\u201377.","journal-title":"Muscle Nerve"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92:e2492\u2013506.","journal-title":"Neurology"},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137.","journal-title":"Neurology"},{"key":"653_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017\u201326.","journal-title":"Lancet"},{"key":"653_CR14","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Darras BT, et al., ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","DOI":"10.1056\/NEJMoa1702752"},{"key":"653_CR15","doi-asserted-by":"crossref","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","DOI":"10.1056\/NEJMoa1710504"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1212\/WNL.94.15_supplement.1132","volume":"94","author":"JW Day","year":"2020","unstructured":"Day JW, Swoboda KJ, Darras BT, et al. Longer-term experience with nusinersen in teenagers and young adults with spinal muscular atrophy: results from the CS2\/CS12 and SHINE studies (1132). Neurology. 2020;94:1132.","journal-title":"Neurology"},{"key":"653_CR17","doi-asserted-by":"crossref","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al., NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356.","DOI":"10.1212\/WNL.92.15_supplement.S25.001"},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","volume":"5","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child Adolesc Health. 2021;5:491\u2013500.","journal-title":"Lancet Child Adolesc Health"},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365.","journal-title":"J Neuromuscul Dis"},{"key":"653_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, Gunther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317\u201325.","journal-title":"Lancet Neurol"},{"key":"653_CR21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91:1166\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74:790\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"653_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Walter MC, Attarian S, et al. Measuring outcomes in adults with spinal muscular atrophy\u2014challenges and future directions\u2014meeting report. J Neuromuscul Dis. 2020;7:523\u201334.","journal-title":"J Neuromuscul Dis"},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O'Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693\u20137.","journal-title":"Neuromuscul Disord"},{"key":"653_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374.","journal-title":"Muscle Nerve"},{"key":"653_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836\u201342.","journal-title":"Muscle Nerve"},{"key":"653_CR27","doi-asserted-by":"crossref","unstructured":"Pera MC, Coratti G, Mazzone ES, et al., iSMAC Consortium Group. Revised upper limb module for spinal muscular atrophy: 12\u00a0month changes. Muscle Nerve. 2019;59:426\u201330.","DOI":"10.1002\/mus.26419"},{"key":"653_CR28","first-page":"S54","volume":"25","author":"V Williams","year":"2019","unstructured":"Williams V, Stull DE, Houghton K, Williams N, Teynor M. Minimal clinically important differences of the Expanded Hammersmith Functional Motor Scale in later-onset spinal muscular atrophy: results from the phase 3 CHERISH trial. J Manag Care Spec Pharm. 2019;25:S54.","journal-title":"J Manag Care Spec Pharm"},{"key":"653_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"653_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"653_CR31","doi-asserted-by":"crossref","unstructured":"Pera MC, Coratti G, Bovis F, et al., iSMAC Group. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8:1622\u201334.","DOI":"10.1002\/acn3.51411"},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/brainsci11091244","volume":"11","author":"S Brakemeier","year":"2021","unstructured":"Brakemeier S, Stolte B, Thimm A, et al. Assessment of bulbar function in adult patients with 5q-SMA Type 2 and 3 under treatment with nusinersen. Brain Sci. 2021;11:1244.","journal-title":"Brain Sci"},{"key":"653_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.812063","volume":"12","author":"A Thimm","year":"2022","unstructured":"Thimm A, Brakemeier S, Kizina K, et al. Assessment of health-related quality of life in adult spinal muscular atrophy under nusinersen treatment-a pilot study. Front Neurol. 2022;12: 812063.","journal-title":"Front Neurol"},{"key":"653_CR34","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","volume":"10","author":"K Kizina","year":"2020","unstructured":"Kizina K, Stolte B, Totzeck A, et al. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen. Sci Rep. 2020;10:11069.","journal-title":"Sci Rep"},{"key":"653_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00415-020-10227-5","volume":"268","author":"C Binz","year":"2021","unstructured":"Binz C, Schreiber-Katz O, Kumpe M, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. J Neurol. 2021;268:950\u201362.","journal-title":"J Neurol"},{"key":"653_CR36","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, et al. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol. 2020;267:2398\u2013407.","journal-title":"J Neurol"},{"key":"653_CR37","doi-asserted-by":"publisher","first-page":"175628641988761","DOI":"10.1177\/1756286419887616","volume":"13","author":"I Cordts","year":"2020","unstructured":"Cordts I, Lingor P, Friedrich B, et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616.","journal-title":"Ther Adv Neurol Disord"},{"key":"653_CR38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jnc.14953","volume":"153","author":"T Kessler","year":"2020","unstructured":"Kessler T, Latzer P, Schmid D, et al. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J Neurochem. 2020;153:650\u201361.","journal-title":"J Neurochem"},{"key":"653_CR39","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1007\/s00415-021-10954-3","volume":"269","author":"S Bonanno","year":"2022","unstructured":"Bonanno S, Zanin R, Bello L, et al. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen. J Neurol. 2022;269:3264\u201375.","journal-title":"J Neurol"},{"key":"653_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/acn3.51340","volume":"8","author":"M Freigang","year":"2021","unstructured":"Freigang M, Wurster CD, Hagenacker T, et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol. 2021;8:1049\u201363.","journal-title":"Ann Clin Transl Neurol"},{"key":"653_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","volume":"41","author":"G Milella","year":"2021","unstructured":"Milella G, Introna A, D\u2019Errico E, et al. Cerebrospinal fluid and clinical profiles in adult type 2\u20133 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience. Clin Drug Investig. 2021;41:775\u201384.","journal-title":"Clin Drug Investig"},{"key":"653_CR42","doi-asserted-by":"crossref","unstructured":"Pane M, Coratti G, Pera MC, et al., Italian ISMAC Group. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9:404\u20139.","DOI":"10.1002\/acn3.51514"},{"key":"653_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","volume":"61","author":"A Veerapandiyan","year":"2020","unstructured":"Veerapandiyan A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve. 2020;61:222\u20136.","journal-title":"Muscle Nerve"},{"key":"653_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","volume":"7","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;7:257\u201368.","journal-title":"J Neuromuscul Dis"},{"key":"653_CR45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","volume":"268","author":"B De Wel","year":"2021","unstructured":"De Wel B, Goosens V, Sobota A, et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol. 2021;268:923\u201335.","journal-title":"J Neurol"},{"key":"653_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.650532","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, et al. Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol. 2021;12: 650532.","journal-title":"Front Neurol"},{"key":"653_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.650535","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, et al. Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front Neurol. 2021;12: 650535.","journal-title":"Front Neurol"},{"key":"653_CR48","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","volume":"13","author":"E Jochmann","year":"2020","unstructured":"Jochmann E, Steinbach R, Jochmann T, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther Adv Neurol Disord. 2020;13:1756286420907803.","journal-title":"Ther Adv Neurol Disord"},{"key":"653_CR49","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11:e317\u201327.","journal-title":"Neurol Clin Pract"},{"key":"653_CR50","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95:e1988\u201398.","journal-title":"Neurology"},{"key":"653_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25:512\u20138.","journal-title":"Eur J Neurol"},{"key":"653_CR52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S, et al. Clinical variability in spinal muscular atrophy type III. Ann Neurol. 2020;88:1109\u201317.","journal-title":"Ann Neurol"},{"key":"653_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE. 2018;13: e0199657.","journal-title":"PLoS ONE"},{"key":"653_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26:126\u201331.","journal-title":"Neuromuscul Disord"},{"key":"653_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nmd.2014.11.008","volume":"25","author":"S Sivo","year":"2015","unstructured":"Sivo S, Mazzone E, Antonaci L, et al. Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscul Disord. 2015;25:212\u20135.","journal-title":"Neuromuscul Disord"},{"key":"653_CR56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti G, Lucibello S, Pera MC, et al. Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromuscul Disord. 2020;30:765\u201371.","journal-title":"Neuromuscul Disord"},{"key":"653_CR57","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nmd.2013.06.001","volume":"23","author":"E Mazzone","year":"2013","unstructured":"Mazzone E, Bianco F, Main M, et al. Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. Neuromuscul Disord. 2013;23:624\u20138.","journal-title":"Neuromuscul Disord"},{"key":"653_CR58","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, Cutrona C, Pera MC, et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;16:430.","journal-title":"Orphanet J Rare Dis"},{"key":"653_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nmd.2021.12.005","volume":"32","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. 2022;32:185\u201394.","journal-title":"Neuromuscul Disord"},{"key":"653_CR60","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/jnnp-2022-ABN.406","volume":"93","author":"L Maggi","year":"2022","unstructured":"Maggi L, Bello L, Bonanno S, et al. Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease. J Neurol Neurosurg Psychiatry. 2022;93:1253\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"653_CR61","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/ene.15501","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study. Eur J Neurol. 2022;29:3337\u201346.","journal-title":"Eur J Neurol"},{"key":"653_CR62","doi-asserted-by":"crossref","unstructured":"Coratti G, Pera MC, Lucibello S, et al; ISMAC group and collaborators. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord. 2020;30:756\u201364.","DOI":"10.1016\/j.nmd.2020.07.005"},{"key":"653_CR63","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","volume":"19","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, et al. Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics. 2022;19:464\u201375.","journal-title":"Neurotherapeutics"},{"key":"653_CR64","doi-asserted-by":"crossref","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283:2008\u201312.","DOI":"10.1001\/jama.283.15.2008"},{"key":"653_CR65","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/ene.15542","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022;29:3666\u201375.","journal-title":"Eur J Neurol"},{"key":"653_CR66","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.27384","volume":"64","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pera MC, Montes J, et al. Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle Nerve. 2021;64:552\u20139.","journal-title":"Muscle Nerve"},{"key":"653_CR67","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genom Hum Genet. 2020;21:231\u201361.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"653_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17:39.","journal-title":"BMC Neurol"},{"key":"653_CR69","doi-asserted-by":"crossref","unstructured":"Swoboda KJ, Scott CB, Crawford TO, et al; Project Cure Spinal Muscular Atrophy Investigators Network. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5:e12140.","DOI":"10.1371\/journal.pone.0012140"},{"key":"653_CR70","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois JM, Bolz S, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol. 2020;27:2586\u201394.","journal-title":"Eur J Neurol"},{"key":"653_CR71","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21:42\u201352.","journal-title":"Lancet Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00653-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:15:27Z","timestamp":1726161327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00653-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tim Hagenacker received grants\/research support from Biogen, Novartis, and Roche, and honoraria or consulting fees from Biogen, Novartis, and Roche. Lorenzo Maggi received a grant from Biogen and honoraria for speaking, and consulting fees or compensation for congress participations from Amicus Therapeutics, Biogen, Janssen Pharmaceutics, Roche, and Sanofi Genzyme. Giorgia Coratti has received honoraria for speaking and compensation for congress participation from AveXis, Biogen, BioLogix, Novartis, and Roche. Bora Youn and Angela D. Paradis are employees of Biogen\u00a0and may hold stock in the company. Stephanie Raynaud is a former employee of Biogen and may have held\u00a0stock in the company at the time of the study. Eugenio Mercuri has served on advisory boards for SMA studies for AveXis, Biogen, Ionis, Novartis, and Roche; as Principal Investigator for ongoing Biogen\/Ionis and Roche clinical trials; and has received funding from Famiglie SMA Italy, Italian Telethon, and SMA Europe.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}